Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2651)	1/6/2010 10:11:41 AM
From: Jibacoa	Respond to of 3722

CYCCP is up 20% but volume is still low at 700 <g> It announced that its CEO will present at a meeting in Frisco a week from today. bigcharts.marketwatch.com CYCCP has 3 orally-available Cyclacel drugs that are in development: Sapacitabine (CYC682), is a cell cycle modulating nucleoside analog, in PII for treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and lung cancer. CYCCP plans to submit an SPA request for a pivotal study with the drug in the 1stQ as it announced on Dec 15. <g> finance.yahoo.com Seliciclib (CYC202) is a cyclin dependent kinase) inhibitor, in PII for treatment of lung cancer and nasopharyngeal cancer and in a PI in combination with sapacitabine. CYC116, an Aurora kinase and VEGFR2 inhibitor, is in a PI in patients with solid tumors. CYCCP's ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair a cream for radiation dermatitis, Numoisyn for xerostomia. With some good news, the stock could get to test the resistance at the $4 level.<g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2651)	4/26/2010 12:57:51 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

BCRX is holding above the support at the $7.25 level, while waiting for the report of its 1stQ results on Wednesday.<g> The 4thQ results came out much better than expected.<g> Revenues were up 60% and earnings 35% compared to the 2008 4thQ and in spite of the poor showing in the 3rdQ <g> On Apr5 Thomson Reuters downgraded it from buy to hold.<g> At its coming annual meeting in May, BCRX expects to increase by another 1.3M the number of shrs outstanding.<g> The ACTAY is $9.88 It seems that with some good news the stock could get to the $10 level.<g> bigcharts.marketwatch.com Bernard